Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Companyâs segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTECH
āļāļ·āđāļāļāļĢāļīāļĐāļąāļBio-Techne Corp
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 09, 1989
āļāļĩāļāļĩāđāļKelderman (Kim)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ3100
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 09
āļāļĩāđāļāļĒāļđāđ614 Mckinley Pl N E
āđāļĄāļ·āļāļMINNEAPOLIS
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ55413
āđāļāļĢāļĻāļąāļāļāđ16123798854
āđāļ§āđāļāđāļāļāđhttps://www.bio-techne.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTECH
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 09, 1989
āļāļĩāļāļĩāđāļKelderman (Kim)
Mr. John L. Higgins
Independent Director
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Ms. Julie L. Bushman
Independent Director
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Mr. James T. (Jim) Hippel
Mr. James T. (Jim) Hippel
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
Mr. David Clair
Investor Relations
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. John L. Higgins
Independent Director
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Ms. Julie L. Bushman
Independent Director
Global X Genomics & Biotechnology ETF
Invesco Biotechnology & Genome ETF
Invesco S&P 500 Equal Weight Health Care ETF
Neuberger Berman Small-Mid Cap ETF
Hilton Small-MidCap Opportunity ETF
iShares Health Innovation Active ETF
American Century Mid Cap Growth Impact ETF
Thrivent Small-Mid Cap ESG ETF
Invesco S&P 500 High Beta ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Global X Genomics & Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ4.29%
Invesco Biotechnology & Genome ETF
āļŠāļąāļāļŠāđāļ§āļ2.92%
Invesco S&P 500 Equal Weight Health Care ETF
Neuberger Berman Small-Mid Cap ETF
āļŠāļąāļāļŠāđāļ§āļ1.78%
VanEck Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ1.73%
Hilton Small-MidCap Opportunity ETF
āļŠāļąāļāļŠāđāļ§āļ1.7%
iShares Health Innovation Active ETF
āļŠāļąāļāļŠāđāļ§āļ1.68%
American Century Mid Cap Growth Impact ETF
āļŠāļąāļāļŠāđāļ§āļ1.47%
Thrivent Small-Mid Cap ESG ETF
āļŠāļąāļāļŠāđāļ§āļ1.34%
Invesco S&P 500 High Beta ETF
āļŠāļąāļāļŠāđāļ§āļ1.06%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
250.90M
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 28, 2025 going ex on Nov 17, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 29, 2025 going ex on Aug 18, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 30, 2025 going ex on May 19, 2025
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ